# Role of Preoperative Thyroid-Stimulating Hormone Levels in the Prediction of Thyroid Hormone Replacement after Hemithyroidectomy

**Authors:** Ramona Paula Fernandes Reckziegel, Lenara Golbert, Erika Laurini de Souza Meyer

PMC · DOI: 10.1055/s-0045-1801852 · 2025-04-15

## TL;DR

This study shows that preoperative TSH levels help predict the need for thyroid hormone replacement after hemithyroidectomy.

## Contribution

The study identifies a specific TSH cutoff (1.21 μIU/mL) that predicts postoperative hypothyroidism risk after hemithyroidectomy.

## Key findings

- 63% of patients required thyroid hormone replacement after hemithyroidectomy.
- Higher preoperative TSH levels were strongly associated with postoperative hypothyroidism.
- A TSH cutoff of 1.21 μIU/mL maximized sensitivity and specificity for predicting hypothyroidism.

## Abstract

Introduction
 Hemithyroidectomy is performed for the treatment of symptomatic unilateral benign nodules, cytologically indeterminate nodules, and some cases of well-differentiated thyroid cancer.

Objective
 To evaluate the frequency of postlobectomy thyroid hormone replacement (THR), and to analyze the clinical-pathological factors predicting L-thyroxine (T4) use in patients undergoing hemithyroidectomy.

Methods
 We conducted an observational, retrospective study in which clinical, biochemical, and anatomopathological parameters were analyzed and correlated with the need for THR after thyroid lobectomy.

Results
 The frequency of postoperative THR was 63%. The preoperative thyroid-stimulating hormone (TSH) level was an important predictor of postoperative THR. When stratifying preoperative TSH levels, the frequencies of T4 replacement in each TSH quartile varied, being more frequent with increasing presurgical TSH levels (
p
 = 0.029). The preoperative cutoff that maximized sensitivity and specificity for the development of hypothyroidism was 1.21 μIU/mL.

Conclusion
 Our results demonstrated a significant frequency of postlobectomy THR. Higher preoperative TSH is a strong risk factor for postsurgical hypothyroidism, and even lower preoperative levels within the normal references do not exclude the risk of thyroid hormone use after thyroid lobectomy.

## Linked entities

- **Chemicals:** L-thyroxine (PubChem CID 5819), T4 (PubChem CID 5819)
- **Diseases:** hypothyroidism (MONDO:0005420), thyroid cancer (MONDO:0002108)

## Full-text entities

- **Diseases:** thyroid lobectomy (MESH:D020232), thyroid cancer (MESH:D013964), hypothyroidism (MESH:D007037)
- **Chemicals:** L-thyroxine (MESH:D013974), Thyroid-Stimulating Hormone (MESH:D013972)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12020584/full.md

---
Source: https://tomesphere.com/paper/PMC12020584